Clinical trials: Chronic Weight Management
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
A Pilot Trial of Nabilone for the Treatment of Obesity
Obesity is a serious health problem which increases the likelihood of developing other life-changing medical conditions. Despite increasing knowledge about the neural and metabolic basis of obesity, the development of effective…
- Trial name
- NCT04801641
- Testing
- Nabilone
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Addiction and Mental Health
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency.
- Trial name
- NCT00261833
- Testing
- Alpha1-proteinase inhibitor
- Where
- 28 sites in United States, Australia and 11 more
- Volunteers
- 180 people
- Sponsor
- CSL Behring
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity.
- Trial name
- NCT05696847
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Chronic Management of Body Weight
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.
- Trial name
- NCT06841445
- Testing
- HRS9531 Tablet
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Fluid Accumulation, Blood Pressure Management
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease.
- Conditions
- Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
- Trial name
- DRIVE-UF (NCT07637110)
- Testing
- Ultrafiltration
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Washington
Muscle Loss, Obesity
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
- Trial name
- QUALITY (NCT06282458)
- Testing
- Enobosarm, Semaglutide
- Where
- 14 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Veru Inc.
Weight Gain
Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis
Methods are needed to help decrease interdialytic weight gains in hemodialysis patients. One potential method for accomplishing this goal is to develop an app for smartphones that allow patients to track their fluid intake…
- Trial name
- NCT03759847
- Testing
- Fluid intake app, Survey
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Obesity
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
- Trial name
- MARITIME-1 (NCT06858839)
- Testing
- Maridebart Cafraglutide
- Where
- 243 sites in United States, Argentina and 15 more
- Volunteers
- 3,853 people
- Sponsor
- Amgen
Stroke, Multiple Sclerosis
Health Promotion and Wellness Program for Adults With Disabling Conditions
The objective of this study is to conduct a randomized controlled pilot study to examine the efficacy, feasibility and safety of the SystemCHANGE™(SC) health promotion and wellness program in adults with disabling conditions.
- Conditions
- Stroke, Multiple Sclerosis, Rheumatoid Arthritis
- Trial name
- NCT01776034
- Testing
- SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Case Western Reserve University
Chronic Pain, Musculoskeletal Pain
Weighted Blanket Use for Adults With Chronic Pain
Chronic pain is a common condition that can affect sleep, daily functioning, and overall quality of life. Many individuals living with chronic pain seek non-medication approaches to help manage their symptoms.
- Conditions
- Chronic Pain, Musculoskeletal Pain, Sleep Disturbance, Pain Disorders
- Trial name
- EMBRACE (NCT07498491)
- Testing
- Weighted Blanket
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National University of Natural Medicine
Chronic Weight Management
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
- Trial name
- NCT07002905
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity, Chronic Kidney Disease
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.
- Trial name
- NCT06396416
- Testing
- Semaglutide, Virtual Weight Management Coaching
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Chronic Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
- Trial name
- NCT00674063
- Testing
- alefacept
- Where
- 17 sites in United States, Canada
- Volunteers
- 78 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2, Obesity
Impact of a Regional Program Agir Sur Sa SantE
The prevention and control of lifestyle-related non-communicable chronic diseases, including diabetes, obesity and cardiovascular disorders, that share common risk factors, has now become a major focus of the World Health…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Hypertension, Dyslipidemias
- Trial name
- NCT02478853
- Testing
- Implementation of a new regional care framework
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Université de Sherbrooke
Chronic Weight Management
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects
The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.
- Trial name
- NCT06671821
- Testing
- HRS-7535
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Chronic Kidney Disease, Hypertension
Lifestyle Intervention In CKD
This research study will test whether a 12-week healthy lifestyle program offered through a cardiac rehabilitation center can help lower blood pressure and improve kidney health in adults with advanced chronic kidney disease.
- Trial name
- CKD-LIFE (NCT07633145)
- Testing
- Multi-component lifestyle intervention, Usual Care Control
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Duke University